Larotinib Mesylate clinical trials
How each study uses Larotinib Mesylate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Larotinib Mesylate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Larotinib Mesylate, phase 3 first.
- Aug 2027Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerPhase 3 · Sunshine Lake Pharma Co., Ltd.
Studies
Open first, then newest update. How each study uses Larotinib Mesylate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT04415853Written as Lerotinib
- Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic FunctionWithdrawnPhase 1Sunshine Lake Pharma Co., Ltd.NCT05048368Written as Larotinib
- A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT05057949Written as Larotinib
- Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene AmplificationCompletedPhase 1/2Sunshine Lake Pharma Co., Ltd.NCT03888092Written as Z650
- Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic CancerTerminatedPhase 1Sunshine Lake Pharma Co., Ltd.NCT04131192Written as Z650